Teclistamab with pomalidomide for relapsed or refractory multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a combination of two drugs, teclistamab and pomalidomide, given in an alternating schedule to see if it helps people whose multiple myeloma has come back or stopped responding to previous treatments. The goal is to improve outcomes with manageable side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with multiple myeloma and it has returned or is resistant to treatment after 1 to 3 prior lines of therapy.
- You have received at least 2 cycles of a drug like daratumumab (an anti-CD38 antibody) and at least 2 cycles of lenalidomide in the past.
- Your cancer shows measurable signs of activity (like a certain level of M-protein or free light chains in your blood or urine).
- You are able to care for yourself (ECOG performance status 0 to 2).
- You have not had treatment with drugs that target BCMA (like certain CAR-T therapies or bispecific antibodies).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of teclistamab (an immunotherapy) and your own immune cells to treat multiple myeloma that has come back or stopped responding to prior treatments. It is for people who have had 1 or 2 prior lines of therapy and have not received a BCMA-targeted treatment before.
This trial tests a combination of two drugs, teclistamab and iberdomide, for people with multiple myeloma that has come back or stopped responding to at least 4 prior treatments. The goal is to see if this combination can work when other options have failed.
This study tests how well teclistamab works for people with multiple myeloma that has come back or not responded to at least three prior treatments. You may be eligible if you are starting teclistamab as part of your regular care.
This trial tests a combination of two drugs—teclistamab (an immunotherapy) and mezigdomide (a targeted pill)—for people with multiple myeloma that has come back or not responded to previous treatments. The goal is to see if this new combination can help when other options have stopped working.
This trial tests whether adding teclistamab to lenalidomide (or using teclistamab alone) helps keep newly diagnosed multiple myeloma from coming back after an autologous stem cell transplant. It’s comparing these options to lenalidomide alone as long-term maintenance.
This Phase 2 trial studies how well teclistamab works when used in combination for people age 65 and older with multiple myeloma. It aims to see whether this treatment can control the cancer safely in older patients who may not do high-dose chemotherapy or stem cell transplant.
Hear when a new Multiple Myeloma Progression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.